RECRUITING

Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during the preeclamptic pregnancy and persists postpartum, despite the remission of clinical symptoms. The purpose of this investigation is to determine the mechanisms contributing to this lasting blood vessel damage caused by reduced endothelial function in women who have had preeclampsia compared to women who had a healthy pregnancy. Identification of these mechanisms and treatment strategies may lead to better clinical management of cardiovascular disease risk in these women. The purpose of this study is to examine the microvascular differences in women who have had preeclampsia following activation of protective angiotensin receptors in the skin. This will help increase understanding of the mechanisms of angiotensin II receptors in these women, and how activation of these receptors may restore microvascular function. In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) the investigators examine the blood vessels in a dime-sized area of the skin.

Official Title

Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia

Quick Facts

Study Start:2023-06-28
Study Completion:2025-06-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05937841

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 45 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * women who had preeclampsia and women who did not have preeclampsia
  2. * 12 weeks to 5 years postpartum
  3. * 18-45 years old
  1. * history of hypertension or metabolic disease before pregnancy
  2. * history of gestational diabetes
  3. * skin diseases
  4. * current tobacco use
  5. * current antihypertensive medication
  6. * statin or other cholesterol-lowering medication
  7. * currently pregnant or planning to become pregnant
  8. * body mass index less than 18.5 kg/m2
  9. * allergy to materials used during the experiment.(e.g. latex),
  10. * known allergy to study drugs

Contacts and Locations

Study Contact

Kelsey Schwartz
CONTACT
319-467-3096
kelsey-schwartz@uiowa.edu

Principal Investigator

Anna Reid-Stanhewicz, PhD
PRINCIPAL_INVESTIGATOR
University of Iowa

Study Locations (Sites)

University of Iowa
Iowa City, Iowa, 52242
United States

Collaborators and Investigators

Sponsor: Anna Stanhewicz, PhD

  • Anna Reid-Stanhewicz, PhD, PRINCIPAL_INVESTIGATOR, University of Iowa

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-06-28
Study Completion Date2025-06-01

Study Record Updates

Study Start Date2023-06-28
Study Completion Date2025-06-01

Terms related to this study

Additional Relevant MeSH Terms

  • Preeclampsia Postpartum